BR0114870A - Tratamento de tumores estromais gastrointestinais - Google Patents

Tratamento de tumores estromais gastrointestinais

Info

Publication number
BR0114870A
BR0114870A BR0114870-2A BRPI0114870A BR0114870A BR 0114870 A BR0114870 A BR 0114870A BR PI0114870 A BRPI0114870 A BR PI0114870A BR 0114870 A BR0114870 A BR 0114870A
Authority
BR
Brazil
Prior art keywords
gastrointestinal stromal
stromal tumors
treatment
tumors
methylpiperazin
Prior art date
Application number
BR0114870-2A
Other languages
English (en)
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J Druker
Jonathan A Fletcher
Heikki Joensuu
Sandra Leta Silberman
David Tuneson
Michael C Heinrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0114870(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0114870A publication Critical patent/BR0114870A/pt
Publication of BRPI0114870B1 publication Critical patent/BRPI0114870B1/pt
Publication of BRPI0114870B8 publication Critical patent/BRPI0114870B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)

Abstract

"TRATAMENTO DE TUMORES ESTROMAIS GASTROINTESTINAIS". 4-(4-Metilpiperazin-1-ilmetil)-N-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamin o)fenil]-benzamida da fórmula I ou um seu sal farmaceuticamente aceitável pode ser usado no tratamento de tumores estromais gastrointestinais.
BRPI0114870-2 2000-10-27 2001-10-26 uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais BRPI0114870B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
US60/243,810 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (3)

Publication Number Publication Date
BR0114870A true BR0114870A (pt) 2004-02-17
BRPI0114870B1 BRPI0114870B1 (pt) 2020-06-16
BRPI0114870B8 BRPI0114870B8 (pt) 2021-05-25

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0114870-2 BRPI0114870B8 (pt) 2000-10-27 2001-10-26 uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais

Country Status (26)

Country Link
US (1) US6958335B2 (pt)
EP (1) EP1332137B1 (pt)
JP (1) JP4386635B2 (pt)
KR (1) KR100885129B1 (pt)
CN (1) CN1276754C (pt)
AT (1) ATE321556T1 (pt)
AU (2) AU2002218262B2 (pt)
BR (1) BRPI0114870B8 (pt)
CA (1) CA2424470C (pt)
CY (1) CY1105055T1 (pt)
CZ (1) CZ303944B6 (pt)
DE (1) DE60118430T2 (pt)
DK (1) DK1332137T3 (pt)
ES (1) ES2260317T3 (pt)
HK (1) HK1058193A1 (pt)
HU (1) HU229106B1 (pt)
IL (2) IL155029A0 (pt)
MX (1) MXPA03003703A (pt)
NO (1) NO324948B1 (pt)
NZ (1) NZ525254A (pt)
PL (1) PL209733B1 (pt)
PT (1) PT1332137E (pt)
RU (1) RU2301066C2 (pt)
SK (1) SK287335B6 (pt)
WO (1) WO2002034727A2 (pt)
ZA (1) ZA200302155B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040167134A1 (en) * 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
JP2004537542A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用
WO2003004006A2 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1401415B1 (en) * 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
DK1401413T3 (da) * 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
CA2461182A1 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
PT1478380E (pt) * 2002-02-27 2006-12-29 Ab Science Utilização de inibidores de tirosina-cinases para tratar doenças do snc
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
CN100467064C (zh) * 2003-09-19 2009-03-11 诺瓦提斯公司 伊马替尼和米哚妥林在制备治疗胃肠道基质肿瘤药物中的应用
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
AU2007296744A1 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
SG174790A1 (en) * 2006-09-11 2011-10-28 Curis Inc Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
IN2014DN07898A (pt) 2012-02-21 2015-04-24 Ranbaxy Lab Ltd
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CA2880236C (en) 2012-07-27 2022-09-13 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
KR20200115607A (ko) 2018-01-31 2020-10-07 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
CN115135308A (zh) 2019-12-30 2022-09-30 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
MX2022008097A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Composiciones de 1-(4-bromo-5-(1-etil-7-(metilamino)-2-oxo-1,2-dih idro-1,6-naftiridin-3-yl)-2-fluorofeil)-3-fenilurea.
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (pt) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体

Also Published As

Publication number Publication date
ES2260317T3 (es) 2006-11-01
PL209733B1 (pl) 2011-10-31
ATE321556T1 (de) 2006-04-15
IL155029A (en) 2009-09-22
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
NO324948B1 (no) 2008-01-07
NO20031833L (no) 2003-04-24
DE60118430T2 (de) 2006-10-26
HUP0301512A2 (hu) 2003-11-28
WO2002034727A2 (en) 2002-05-02
JP2004512328A (ja) 2004-04-22
KR100885129B1 (ko) 2009-02-23
MXPA03003703A (es) 2005-01-25
NZ525254A (en) 2006-02-24
CZ20031152A3 (en) 2004-04-14
KR20030051656A (ko) 2003-06-25
SK5182003A3 (en) 2004-02-03
CN1276754C (zh) 2006-09-27
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
DK1332137T3 (da) 2006-07-17
EP1332137A2 (en) 2003-08-06
PL362148A1 (en) 2004-10-18
JP4386635B2 (ja) 2009-12-16
EP1332137B1 (en) 2006-03-29
HK1058193A1 (en) 2004-05-07
HU229106B1 (en) 2013-07-29
US20040023976A1 (en) 2004-02-05
CA2424470C (en) 2009-06-09
CA2424470A1 (en) 2002-05-02
BRPI0114870B1 (pt) 2020-06-16
SK287335B6 (sk) 2010-07-07
AU2002218262B2 (en) 2005-09-29
AU1826202A (en) 2002-05-06
ZA200302155B (en) 2004-04-22
DE60118430D1 (de) 2006-05-18
IL155029A0 (en) 2003-10-31
CN1622808A (zh) 2005-06-01
CY1105055T1 (el) 2010-03-03
BRPI0114870B8 (pt) 2021-05-25
CZ303944B6 (cs) 2013-07-10
RU2301066C2 (ru) 2007-06-20

Similar Documents

Publication Publication Date Title
BR0114870A (pt) Tratamento de tumores estromais gastrointestinais
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
NO20052755D0 (no) Krystallmodifikasjon av et N-fenyl-2-pyrimidinaminderivat, fremgangsmate for dens fremstilling og dens anvendelse.
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 241/00

Ipc: A61K 31/506 (2011.01), A61P 35/00 (2011.01)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.005155/2020-65 ORIGEM: JUIZO FEDERAL DA 31A VF DO RIO DE JANEIRO (TRF2) PROCESSO NO: 5034049-12.2020.4.02.5101 NULIDADE DE ATO ADMINISTRATIVO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA. REU(S): NOVARTIS AG E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL (INPI)

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI NO 52402.003026/2021-13 ORIGEM: 31O VF DO RIO DE JANEIRO PROCESSO NO: 5018956-72.2021.4.02.5101 NULIDADE DA PATENTE DE INVENCAO COM PEDIDO DE ANTECIPACAO DE TUTELA AUTOR: EMS S/A , GERMED FARMACEUTICA LTDA E LEGRAND PHARMA INDUSTRIA FARMACEUTICA LTDA REU(S): NOVARTIS AG E INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF